Stephen Wilson joins Cytocom to serve as head of global innovation

Stephen Wilson joins Cytocom to serve as head of global innovation

FORT COLLINS -- Cytocom, Inc . announced Stephen Wilson has joined the company as its head of global innovations, effective April 19. Wilson arrives at Cytocom after spending nearly 25... Read More

Wednesday April 21, 2021 0 comments Tags: Fort Collins, Cytocom, Stephen Wilson, Mike Handley

Cytocom receives FDA clearance of IND for Phase 2 clinical trial of CYTO-205 as treatment for COVID-19

Cytocom receives FDA clearance of IND for Phase 2 clinical trial of CYTO-205 as treatment for COVID-19

FORT COLLINS -- Cytocom, Inc. announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 2 clinical trial to evaluate the safety... Read More

Thursday March 18, 2021 0 comments Tags: Fort Collins, Cytocom, CYTO-205, Michael Handley, FDA

Cytocom in proposed merger with Cleveland BioLabs after SEC filing

Cytocom in proposed merger with Cleveland BioLabs after SEC filing

FORT COLLINS/ BUFFALO, N.Y. -- New York-based Cleveland BioLabs, Inc. (NASDAQ: CBLI), a biopharmaceutical company developing novel approaches to activate the immune system, filed a registration... Read More

Thursday February 18, 2021 0 comments Tags: Fort Collins, Cytocom, Cleveland BioLabs, Michael Handley

Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19

Cytocom updates investigational new drug application for phase 2 clinical trial of CYTO-205 for treatment of COVID-19

FORT COLLINS -- Cytocom, Inc. today provided an update regarding its CYTO-200 portfolio of clinical programs. Cytocom said it has submitted an Investigational New Drug (IND) application with... Read More

Tuesday February 16, 2021 0 comments Tags: Fort Collins, Cytocom, COVID-19, CYTO-205, Michael Handley